Australia Chimeric Therapeutics rises on first enrolment in cancer cell therapy trial

Chimeric Therapeutics

22/07/2024 03:45

** Shares of Chimeric Therapeutics  CHM.AX  rise as much as
15.8% to A$0.022, hitting their highest level since May 27
    ** Stock set for best day since March 1, if current gains
hold
    ** Cell therapy co enrols first participant in Phase 1/2
multi-centre clinical trial for CHM CDH17 cell therapy
    ** CHM CD17 is in preclinical development, aims for complete
eradication of tumours in seven types of cancer
    ** About 1.8 mln shares change hands, 1.3 times the 30-day
average volume
    ** Stock down 45.7% this year, as of last close

 (Reporting by Shivangi Lahiri in Bengaluru)
 ((shivangi.lahiri@thomsonreuters.com))